Abstract
The present study aimed to explore the genotypic and phenotypic characteristics of biofilm formation in Bulgarian nosocomial Stenotrophomonas maltophilia isolates (n = 221) during the period 2011–2022, by screening for the presence of biofilm-associated genes (BAG) (spgM, rmlA and rpfF), their mutational variability, and assessment of the adherent growth on a polystyrene surface. The methodology included: PCR amplification, whole-genome sequencing (WGS) and crystal violet microtiter plate assay for biofilm quantification. The overall incidence of BAG was: spgM 98.6%, rmlA 86%, and rpfF 66.5%. The most prevalent genotype was spgM+/rmlA+/rpfF+ (56.1%), followed by spgM+/rmlA+/rpfF- (28.5%), and spgM+/rmlA-/rpfF+ (9.5%), with their significant predominance in lower respiratory tract isolates compared to those with other origin (P < 0.001). All strains examined were characterized as strong biofilm producers (OD550 from 0.224 ± 0.049 to 2.065 ± 0.023) with a single exception that showed a weak biofilm-forming ability (0.177 ± 0.024). No significant differences were observed in the biofilm formation according to the isolation source, as well as among COVID-19 and non-COVID-19 isolates (1.256 ± 0.028 vs. 1.348 ± 0.128, respectively). Also, no correlation was found between the biofilm amounts and the corresponding genotypes. WGS showed that the rmlA accumulated a larger number of variants (0.0086 per base) compared to the other BAG, suggesting no critical role of its product to the biofilm formation. Additionally, two of the isolates were found to harbour class 1 integrons (7-kb and 2.6-kb sized, respectively) containing sul1 in their 3′ conservative ends, which confers sulfonamide resistance. To the best of our knowledge, this is the first study on S. maltophilia biofilm formation in Bulgaria, which also identifies novel sequence types (ST819, ST820 and ST826). It demonstrates the complex nature of this adaptive mechanism in the multifactorial pathogenesis of biofilm-associated infections.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev 2012; 25: 2–41. https://doi.org/10.1128/CMR.00019-11.
-
2.
Insuwanno W, Kiratisin P, Jitmuang A. Stenotrophomonas maltophilia infections: clinical characteristics and factors associated with mortality of hospitalized patients. Infect Drug Resist 2020; 13: 1559–66. https://doi.org/10.2147/IDR.S253949.
-
3.
Demiraslan H, Sevim M, Pala Ç, Durmaz S, Berk V, Kaynar L, et al. Risk factors influencing mortality related to Stenotrophomonas maltophilia infection in hematology-oncology patients. Int J Hematol 2013; 97: 414–20. https://doi.org/10.1007/s12185-013-1296-x.
-
4.
Kim SH, Cha MK, Kang CI, Ko JH, Huh K, Cho SY, et al. Pathogenic significance of hemorrhagic pneumonia in hematologic malignancy patients with Stenotrophomonas maltophilia bacteremia: clinical and microbiological analysis. Eur J Clin Microbiol Infect Dis 2019; 38: 285–95. https://doi.org/10.1007/s10096-018-3425-1.
-
5.
Waters V, Atenafu EG, Lu A, Yau Y, Tullis E, Ratjen F. Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. J Cyst Fibros 2013; 12: 482–6. https://doi.org/10.1016/j.jcf.2012.12.006.
-
6.
Yang S, Hua M, Liu X, Du C, Pu L, Xiang P, et al. Bacterial and fungal co-infections among COVID-19 patients in intensive care unit. Microbes Infect 2021; 23: 104806. https://doi.org/10.1016/j.micinf.2021.104806.
-
7.
Ishikawa K, Nakamura T, Kawai F, Uehara Y, Mori N. Stenotrophomonas maltophilia infection associated with COVID-19: a case series and literature review. Am J Case Rep 2022; 23: e936889. https://doi.org/10.12659/AJCR.936889.
-
8.
Elsheredy A, Elsheikh A, Ghazal A, Shawky S. Prevalence of trimethoprim/sulfamethoxazole resistance genes among Stenotrophomonas maltophilia clinical isolates in Egypt. Acta Microbiol Immunol Hung 2022; 69: 56–60. https://doi.org/10.1556/030.2021.01568.
-
9.
Flores-Treviño S, Bocanegra-Ibarias P, Camacho-Ortiz A, Morfín-Otero R, Salazar-Sesatty HA, Garza-González E. Stenotrophomonas maltophilia biofilm: its role in infectious diseases. Expert Rev Anti Infect Ther 2019; 17: 877–93. https://doi.org/10.1080/14787210.2019.1685875.
-
10.
Strateva T, Trifonova A, Savov E, Mitov I, Peykov S. Characterization of an extensively drug-resistant Stenotrophomonas maltophilia clinical isolate with strong biofilm formation ability from Bulgaria. Infect Dis (Lond) 2020; 52: 841–5. https://doi.org/10.1080/23744235.2020.1792545.
-
11.
Trifonova A, Strateva T. Stenotrophomonas maltophilia – a low-grade pathogen with numerous virulence factors. Infect Dis (Lond) 2019; 51: 168–78. https://doi.org/10.1080/23744235.2018.1531145.
-
12.
Zhuo C, Zhao QY, Xiao SN. The impact of spgM, rpfF, rmlA gene distribution on biofilm formation in Stenotrophomonas maltophilia. PLoS One 2014; 9: e108409. https://doi.org/10.1371/journal.pone.0108409.
-
13.
Gallo SW, Ramos PL, Ferreira CA, Oliveira SD. A specific polymerase chain reaction method to identify Stenotrophomonas maltophilia. Mem Inst Oswaldo Cruz 2013; 108: 390–1. https://doi.org/10.1590/S0074-02762013000300020.
-
14.
Rodriguez -R LM, Gunturu S, Harvey WT, Rosselló-Mora R, Tiedje JM, Cole JR, et al. The Microbial Genomes Atlas (MiGA) webserver: taxonomic and gene diversity analysis of Archaea and Bacteria at the whole genome level. Nucleic Acids Res 2018; 46: 282–8. https://doi.org/10.1093/nar/gky467.
-
15.
Soto SM, Smithson A, Horcajada JP, Martinez JA, Mensa JP, Vila J. Implication of biofilm formation in the persistence of urinary tract infection caused by uropathogenic Escherichia coli. Clin Microbiol Infect 2006; 12: 1034–6. https://doi.org/10.1111/j.1469-0691.2006.01543.x.
-
16.
Stepanović S, Vuković D, Hola V, Di Bonaventura G, Djukić S, Cirković I, et al. Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. APMIS 2007; 115: 891–9. https://doi.org/10.1111/j.1600-0463.2007.apm_630.x.
-
17.
Hubenova Y, Hubenova E, Manasiev Y, Peykov S, Mitov M. Draft genome sequence of Paenibacillus profundus YoMME, a new exoelectrogenic gram-positive bacterium. Microbiol Resour Announc 2022; 11(5): e0023522. https://doi.org/10.1128/mra.00235-22.
-
18.
Afgan E, Baker D, Batut B, van den Beek M, Bouvier D, Cech M, et al. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. Nucleic Acids Res 2018; 46: 537–44. https://doi.org/10.1093/nar/gky379.
-
19.
Peykov S, Stratev S, Kirov B, Gergova R, Strateva T. First detection of a colistin-resistant Klebsiella aerogenes isolate from a critically ill patient with septic shock in Bulgaria. Acta Microbiol Immunol Hung 2022; 69: 209–14. https://doi.org/10.1556/030.2022.01833.
-
20.
Pompilio A, Pomponio S, Crocetta V, Gherardi G, Verginelli F, Fiscarelli E, et al. Phenotypic and genotypic characterization of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis: genome diversity, biofilm formation, and virulence. BMC Microbiol 2011; 11: 159. https://doi.org/10.1186/1471-2180-11-159.
-
21.
Madi H, Lukić J, Vasiljević Z, Biočanin M, Kojić M, Jovčić B, et al. Genotypic and phenotypic characterization of Stenotrophomonas maltophilia strains from a pediatric tertiary care hospital in Serbia. PLoS One. 2016; 11 (10): e0165660. https://doi.org/10.1371/journal.pone.0165660.
-
22.
Bostanghadiri N, Ghalavand Z, Fallah F, Yadegar A, Ardebili A, Tarashi S, et al. Characterization of phenotypic and genotypic diversity of Stenotrophomonas maltophilia strains isolated from selected hospitals in Iran. Front Microbiol 2019; 10: 1191. https://doi.org/10.3389/fmicb.2019.01191.
-
23.
Azimi A, Aslanimehr M, Yaseri M, Shadkam M, Douraghi M. Distribution of smf-1, rmlA, spgM and rpfF genes among Stenotrophomonas maltophilia isolates in relation to biofilm-forming capacity J Glob Antimicrob Resist 2020; 23: 321–6. https://doi.org/10.1016/j.jgar.2020.10.011.
-
24.
Bostanghadiri N, Ardebili A, Ghalavand Z, Teymouri S, Mirzarazi M, Goudarzi M, et al. Antibiotic resistance, biofilm formation, and biofilm-associated genes among Stenotrophomonas maltophilia clinical isolates. BMC Res Notes 2021; 14: 151. https://doi.org/10.1186/s13104-021-05567-y.
-
25.
Huang TP, Somers EB, Wong ACL. Differential biofilm formation and motility associated with lipopolysaccharide/exopolysaccharide-coupled biosynthetic genes in Stenotrophomonas maltophilia. J Bacteriol. 2006; 188 (8): 3116-3120. https://doi.org/10.1128/JB.188.8.3116-3120.2006.
-
26.
Huedo P, Yero D, Martinez-Servat S, Ruyra À, Roher N, Daura X, et al. Decoding the genetic and functional diversity of the DSF quorum-sensing system in Stenotrophomonas maltophilia. Front Microbiol 2015; 6: 761. https://doi.org/10.3389/fmicb.2015.00761.
-
27.
Alcaraz E, Garcia C, Friedman L, de Rossi BP. The rpf/DSF signalling system of Stenotrophomonas maltophilia positively regulates biofilm formation, production of virulence-associated factors and β-lactamase induction. FEMS Microbiol Lett 2019; 366: fnz069. https://doi.org/10.1093/femsle/fnz069.
-
28.
Flores-Treviño S, Gutiérrez-Ferman JL, Morfín-Otero R, Rodríguez-Noriega E, Estrada-Rivadeneyra D, Rivas-Morales C, et al. Stenotrophomonas maltophilia in Mexico: antimicrobial resistance, biofilm formation and clonal diversity. J Med Microbiol 2014; 63: 1524–30. https://doi.org/10.1099/jmm.0.074385-0.
-
29.
Pompilio A, Ranalli M, Piccirilli A, Perilli M, Vukovic D, Savic B, et al. Biofilm formation among Stenotrophomonas maltophilia isolates has clinical relevance: the ANSELM prospective multicenter study. Microorganisms 2021; 9: 49. https://doi.org/10.3390/microorganisms9010049.
-
30.
Gallo SW, Figueiredo TP, Bessa MC, Pagnussatti VE, Ferreira CA, Oliveira SD. Isolation and characterization of Stenotrophomonas maltophilia isolates from a Brazilian hospital. Microb Drug Resist 2016; 22: 688–95. https://doi.org/10.1089/mdr.2015.0306.
-
31.
Alcaraz E, Garcia C, Papalia M, Vay C, Friedman L, Passerini de Rossi B. Stenotrophomonas maltophilia isolated from patients exposed to invasive devices in a university hospital in Argentina: molecular typing, susceptibility and detection of potential virulence factors. J Med Microbiol 2018; 67: 992–1002. https://doi.org/10.1099/jmm.0.000764.
-
32.
Pompilio A, Crocetta V, Ghosh D, Chakrabarti M, Gherardi G, Vitali LA, et al. Stenotrophomonas maltophilia phenotypic and genotypic diversity during a 10-year colonization in the lungs of a cystic fibrosis patient. Front Microbiol 2016; 7: 1551. https://doi.org/10.3389/fmicb.2016.01551.
-
33.
Cruz-Córdova A, Mancilla-Rojano J, Luna-Pineda VM, Escalona-Venegas G, Cázares-Domínguez V, Ormsby C, et al. Molecular epidemiology, antibiotic resistance, and virulence traits of Stenotrophomonas maltophilia strains associated with an outbreak in a Mexican tertiary care hospital. Front Cell Infect Microbiol 2020; 10: 50. https://doi.org/10.3389/fcimb.2020.00050.
Please, download the file from HERE
Editorial Office:
Akadémiai Kiadó Zrt.
Budafoki út 187-187, A/3, H-1117 Budapest, Hungary
Editorial Correspondence:
Acta Microbiologica et Immunologica Hungarica
Institute of Medical Microbiology
Semmelweis University
P.O. Box 370
H-1445 Budapest, Hungary
Phone: + 36 1 459 1500 ext. 56101
Fax: (36 1) 210 2959
E-mail: amih@med.semmelweis-univ.hu
Indexing and Abstracting Services:
- Biological Abstracts
- BIOSIS Previews
- CAB Abstracts
- CABELLS Journalytics
- Chemical Abstracts
- Global Health
- Index Medicus
- Index Veterinarius
- Medline
- Referativnyi Zhurnal
- SCOPUS
- Science Citation Index Expanded
| 2021 | |
|---|---|
| Web of Science | |
| Total Cites WoS |
696 |
| Journal Impact Factor | 2,298 |
| Rank by Impact Factor | Immunology 141/161 Microbiology 118/136 |
| Impact Factor without Journal Self Cites |
2,143 |
| 5 Year Impact Factor |
1,925 |
| Journal Citation Indicator | 0,39 |
| Rank by Journal Citation Indicator | Immunology 146/177 Microbiology 129/157 |
| Scimago | |
| Scimago H-index |
29 |
| Scimago Journal Rank |
0,362 |
| Scimago Quartile Score | Immunology and Microbiology (miscellaneous) (Q3) Medicine (miscellaneous) (Q3) |
| Scopus | |
| Scopus Cite Score |
3,6 |
| Scopus CIte Score Rank |
General Immunology and Microbiology 26/56 (Q2) Infectious Diseases 149/295 (Q3) Microbiology (medical) 66/118 (Q3) |
| Scopus SNIP |
0,598 |
| 2020 | |
| Total Cites | 662 |
| WoS | |
| Journal Impact Factor |
2,048 |
| Rank by | Immunology 145/162(Q4) |
| Impact Factor | Microbiology 118/137 (Q4) |
| Impact Factor | 1,904 |
| without | |
| Journal Self Cites | |
| 5 Year | 0,671 |
| Impact Factor | |
| Journal | 0,38 |
| Citation Indicator | |
| Rank by Journal | Immunology 146/174 (Q4) |
| Citation Indicator | Microbiology 120/142 (Q4) |
| Citable | 42 |
| Items | |
| Total | 40 |
| Articles | |
| Total | 2 |
| Reviews | |
| Scimago | 28 |
| H-index | |
| Scimago | 0,439 |
| Journal Rank | |
| Scimago | Immunology and Microbiology (miscellaneous) Q4 |
| Quartile Score | Medicine (miscellaneous) Q3 |
| Scopus | 438/167=2,6 |
| Scite Score | |
| Scopus | General Immunology and Microbiology 31/45 (Q3) |
| Scite Score Rank | |
| Scopus | 0,760 |
| SNIP | |
| Days from | 225 |
| submission | |
| to acceptance | |
| Days from | 118 |
| acceptance | |
| to publication | |
| Acceptance | 19% |
| Rate |
| 2019 | |
|---|---|
| Total Cites WoS |
485 |
| Impact Factor | 1,086 |
| Impact Factor without Journal Self Cites |
0,864 |
| 5 Year Impact Factor |
1,233 |
| Immediacy Index |
0,286 |
| Citable Items |
42 |
| Total Articles |
40 |
| Total Reviews |
2 |
| Cited Half-Life |
5,8 |
| Citing Half-Life |
7,7 |
| Eigenfactor Score |
0,00059 |
| Article Influence Score |
0,246 |
| % Articles in Citable Items |
95,24 |
| Normalized Eigenfactor |
0,07317 |
| Average IF Percentile |
7,690 |
| Scimago H-index |
27 |
| Scimago Journal Rank |
0,352 |
| Scopus Scite Score |
320/161=2 |
| Scopus Scite Score Rank |
General Immunology and Microbiology 35/45 (Q4) |
| Scopus SNIP |
0,492 |
| Acceptance Rate |
16% |
| Acta Microbiologica et Immunologica Hungarica | |
|---|---|
| Publication Model | Online only Hybrid |
| Submission Fee | none |
| Article Processing Charge | 1100 EUR/article |
| Regional discounts on country of the funding agency | World Bank Lower-middle-income economies: 50% World Bank Low-income economies: 100% |
| Further Discounts | Editorial Board / Advisory Board members: 50% Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100% |
| Subscription fee 2023 | Online subsscription: 680 EUR / 832 USD Print + online subscription: 760 EUR / 930 USD |
| Subscription Information | Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content. |
| Purchase per Title | Individual articles are sold on the displayed price. |
| Acta Microbiologica et Immunologica Hungarica | |
|---|---|
| Language | English |
| Size | A4 |
| Year of Foundation |
1954 |
| Volumes per Year |
1 |
| Issues per Year |
4 |
| Founder | Magyar Tudományos Akadémia |
| Founder's Address |
H-1051 Budapest, Hungary, Széchenyi István tér 9. |
| Publisher | Akadémiai Kiadó |
| Publisher's Address |
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245. |
| Responsible Publisher |
Chief Executive Officer, Akadémiai Kiadó |
| ISSN | 1217-8950 (Print) |
| ISSN | 1588-2640 (Online) |
Monthly Content Usage
| Abstract Views | Full Text Views | PDF Downloads | |
|---|---|---|---|
| Aug 2022 | 0 | 0 | 0 |
| Sep 2022 | 0 | 0 | 0 |
| Oct 2022 | 0 | 0 | 0 |
| Nov 2022 | 0 | 0 | 0 |
| Dec 2022 | 0 | 0 | 0 |
| Jan 2023 | 174 | 6 | 5 |
| Feb 2023 | 0 | 0 | 0 |
Copyright Akadémiai Kiadó
AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.
Copyright Akadémiai Kiadó AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.
Powered by PubFactory